Ketamine-related harm does not consistently present through established markers of dependence.

 

Instead, it often develops through transitional changes — shifts in use, cognition, behaviour, and physical functioning that emerge progressively over time.

 

These changes can be difficult to recognise within traditional assessment frameworks, particularly in the absence of clear dependence or social breakdown.

​

Sentinel Symptoms

 

KASPR places emphasis on the identification of sentinel symptoms.

 

Sentinel symptoms are early indicators of change — signs that ketamine-related harm is emerging or progressing, even where this may not yet be reflected in conventional diagnostic criteria.

 

They are not defined by thresholds of severity, but by their position within a developing pattern of risk.

 

Examples may include:

​

• emerging urinary changes (e.g. increased frequency, nocturia)

• subtle cognitive shifts (attention, memory, processing)

• changes in emotional regulation or dissociative use

• increasing preoccupation with use or shifts in pattern and context

 

Individually, these may appear non-specific.
Taken together, they signal transition — movement from lower to higher levels of risk.

​

Why Sentinel Symptoms Matter

 

Recognising sentinel symptoms allows for earlier and more meaningful intervention.

 

Without this, emerging harm may:

​

• go unrecognised

• be misinterpreted

• or fall below thresholds for action

 

This is particularly important in ketamine use, where:

​

• harm may progress rapidly

• physical complications can develop alongside ongoing use

• presentations do not reliably trigger traditional diagnostic responses

 

Focusing on sentinel symptoms shifts clinical attention from:

“Is there a problem?”

to

“How is this changing, and what does that mean for intervention?”

 

What KASPR Provides

 

KASPR (Ketamine Assessment, Screening & Progression Risk) provides a structured way to organise these observations within everyday clinical practice.

 

It supports practitioners to:

​

• recognise patterns of emerging and progressing harm

• understand the factors shaping risk

• guide intervention in a proportionate and targeted way

 

KASPR is designed to be brief, practical, and applicable across services.

​

• 12 items across three domains

• Typically completed in 5–10 minutes

• Demonstrates strong inter-rater reliability (ICC = 0.83)

 

Three Interacting Domains

 

KASPR organises clinical understanding across three domains:

Exposure | Drivers | Harm

 

These domains provide a structured way to interpret sentinel symptoms and understand how risk is developing.

​

They do not operate in isolation — their interaction shapes both presentation and clinical response.

​

Exposure

 

Exposure describes the pattern and intensity of ketamine use over time.

This includes frequency, quantity, duration, and changes in use.

 

It helps identify escalation, variability, and level of contact with the substance — but does not, on its own, explain harm.

 

Drivers

 

Drivers describe the psychological and behavioural processes that maintain use.

 

These may include dissociation, emotional regulation, coping strategies, habit formation, and reinforcement patterns.

 

They explain why use continues or escalates, even where harm is present.

 

Harm

 

Harm refers to the physical, cognitive, and functional consequences associated with ketamine use.

 

This includes urinary symptoms, cognitive effects, psychological impact, and changes in day-to-day functioning.

 

Harm may develop rapidly and independently of established dependence.

From Recognition to Understanding

 

KASPR is not a checklist, but a framework for organising clinical understanding.

 

By identifying sentinel symptoms and interpreting them across Exposure, Drivers, and Harm, practitioners can:

​

• identify the dominant factors shaping risk

• understand how presentations are developing

• determine where intervention should be focused